Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
Breast Cancer Risk Increases With Repeated CT Imaging
Scatter Radiation from Mammography Presents No Increased Cancer Risk
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
NCI-Approved CTEP Trials For the Month of December
FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer
Trending Stories
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster
- Bonnie Addario, lung cancer survivor and advocate, dies at 77
- Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines
